Journal article

Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat

Stefano Mangiola, Ryan Stuchbery, Patrick McCoy, Ken Chow, Natalie Kurganovs, Michael Kerger, Anthony Papenfuss, Christopher M Hovens, Niall M Corcoran



Prostate cancer is a leading cause of morbidity and cancer-related death worldwide. Androgen deprivation therapy (ADT) is the cornerstone of management for advanced disease. The use of these therapies is associated with multiple side effects, including metabolic syndrome and truncal obesity. At the same time, obesity has been associated with both prostate cancer development and disease progression, linked to its effects on chronic inflammation at a tissue level. The connection between ADT, obesity, inflammation and prostate cancer progression is well established in clinical settings; however, an understanding of the changes in adipose tissue at the molecular level induced by castration thera..

View full abstract


Awarded by Victorian Cancer Agency Early Career Seed Grant

Funding Acknowledgements

Stefano Mangiola is supported by the David Mayor PhD Scholarship from the Prostate Cancer Research Foundation. Ken Chow is supported by a Postgraduate Medical Research Scholarship from the Prostate Cancer Research Fund and the Australian Government Research Training Program Scholarship provided by the Australian Commonwealth Government and the University of Melbourne. Niall M Corcoran is supported by a David Bickart Clinician Research Fellowship from the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne, as well a Movember - Distinguished Gentleman's Ride Clinician Scientist Award through Prostate Cancer Foundation of Australia's Research Programme. Sample analysis was funded through a Victorian Cancer Agency Early Career Seed Grant to N M C (ECSG14010).